Volgen
Dick de Zeeuw
Dick de Zeeuw
Emeritus Professor Clinical Pharmacology, University of Groningen, University Medical Center
Geverifieerd e-mailadres voor umcg.nl
Titel
Geciteerd door
Geciteerd door
Jaar
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
BM Brenner, ME Cooper, D De Zeeuw, WF Keane, WE Mitch, HH Parving, ...
New England journal of medicine 345 (12), 861-869, 2001
95032001
Heart disease and stroke statistics 2005 update
American Heart Association
http://www. americanheart. org/statistics/, 2005
8533*2005
Canagliflozin and cardiovascular and renal events in type 2 diabetes
B Neal, V Perkovic, KW Mahaffey, D De Zeeuw, G Fulcher, N Erondu, ...
New England Journal of Medicine 377 (7), 644-657, 2017
76092017
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy
V Perkovic, MJ Jardine, B Neal, S Bompoint, HJL Heerspink, ...
New England journal of medicine 380 (24), 2295-2306, 2019
48962019
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo …
C Baigent, MJ Landray, C Reith, J Emberson, DC Wheeler, C Tomson, ...
The Lancet 377 (9784), 2181-2192, 2011
29172011
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo …
C Baigent, MJ Landray, C Reith, J Emberson, DC Wheeler, C Tomson, ...
The Lancet 377 (9784), 2181-2192, 2011
29172011
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
MA Pfeffer, EA Burdmann, CY Chen, ME Cooper, D De Zeeuw, ...
New England Journal of Medicine 361 (21), 2019-2032, 2009
24052009
Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population
HL Hillege, V Fidler, GFH Diercks, WH van Gilst, D de Zeeuw, ...
Circulation 106 (14), 1777-1782, 2002
17822002
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
HH Parving, BM Brenner, JJV McMurray, D De Zeeuw, SM Haffner, ...
New England Journal of Medicine 367 (23), 2204-2213, 2012
16142012
Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis
TH Jafar, PC Stark, CH Schmid, M Landa, G Maschio, PE De Jong, ...
Annals of internal medicine 139 (4), 244-252, 2003
15032003
Renal function, neurohormonal activation, and survival in patients with chronic heart failure
HL Hillege, ARJ Girbes, PJ De Kam, F Boomsma, D De Zeeuw, ...
Circulation 102 (2), 203-210, 2000
14172000
Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement
EL Knight, JC Verhave, D Spiegelman, HL Hillege, D De Zeeuw, ...
Kidney international 65 (4), 1416-1421, 2004
13322004
Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data
TH Jafar, CH Schmid, M Landa, I Giatras, R Toto, G Remuzzi, G Maschio, ...
Annals of internal medicine 135 (2), 73-87, 2001
13262001
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL
D De Zeeuw, G Remuzzi, HH Parving, WF Keane, Z Zhang, S Shahinfar, ...
Kidney international 65 (6), 2309-2320, 2004
12272004
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure
HL Hillege, D Nitsch, MA Pfeffer, K Swedberg, JJV McMurray, S Yusuf, ...
Circulation 113 (5), 671-678, 2006
11782006
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease
D De Zeeuw, T Akizawa, P Audhya, GL Bakris, M Chin, H Christ-Schmidt, ...
New England Journal of Medicine 369 (26), 2492-2503, 2013
10272013
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy
D De Zeeuw, G Remuzzi, HH Parving, WF Keane, Z Zhang, S Shahinfar, ...
Circulation 110 (8), 921-927, 2004
10212004
Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity
HL Hillege, WMT Janssen, AAA Bak, GFH Diercks, DE Grobbee, H Crijns, ...
Journal of internal medicine 249 (6), 519-526, 2001
9092001
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial
D De Zeeuw, R Agarwal, M Amdahl, P Audhya, D Coyne, T Garimella, ...
The Lancet 376 (9752), 1543-1551, 2010
8842010
Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetes
HJ Lambers Heerspink, D De Zeeuw, L Wie, B Leslie, J List
Diabetes, Obesity and Metabolism 15 (9), 853-862, 2013
8732013
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20